The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a ri

The European healthtech and medtech sectors in 2024 and 2025 have transitioned into a phase of rigorous professionalisation, where the primary challenge is no longer a scarcity of capital but the successful navigation of complex regulatory, clinical, and reimbursement frameworks. This maturation has necessitated a new class of mentors and advisors, often referred to as "translators", who possess the specialised fluency required to bridge the gap between academic research hosp

In an era of accelerated technological change, the healthcare technology (healthtech) sector stands at a unique and complex intersection. Unlike conventional industries, healthtech operates in a domain where the stakes extend beyond market share to encompass patient safety, clinical efficacy, and systemic trust. The traditional benchmark of success, "product-market fit," is therefore a necessary but fundamentally insufficient measure for a healthtech venture.

The German Digital Health Act (DiGA), a foundational element of Germany's broader digital healthcare transformation, represents a pioneering legislative initiative to integrate digital health applications into mainstream medical care. Initiated by the Digital Healthcare Act (DVG) in 2019 and further bolstered by the Digital Act (DigiG) in 2024, this framework enables "apps on prescription" to be reimbursed by statutory health insurers, covering approximately 90% of the German